At AllStripes, we are dedicated to unlocking new treatments for people affected by rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem-solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic...

At AllStripes, we are dedicated to unlocking new treatments for people affected by rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic...

At AllStripes, we are dedicated to unlocking new treatments for people with rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic work...

At AllStripes, we are dedicated to unlocking new treatments for people affected by rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic...

At AllStripes, we are dedicated to unlocking new treatments for people with rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic work...

At AllStripes, we are dedicated to unlocking new treatments for people affected by rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem-solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic...

At AllStripes, we are dedicated to unlocking new treatments for people affected by rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic...

At AllStripes, we are dedicated to unlocking new treatments for people affected by rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem-solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic...

At AllStripes, we are dedicated to unlocking new treatments for people with rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic work...

At AllStripes, we are dedicated to unlocking new treatments for people affected by rare disease. There are 7,000 rare diseases affecting 1 in 10 people globally, yet less than 5% of conditions have an FDA-approved therapy. The rare disease drug R&D market is growing at an unprecedented rate, making up over 50% of all novel drugs approved by the FDA in the last year. AllStripes’ two-sided consumer-facing and enterprise software platform serves 1) rare disease patients by showing them their own impact on drug development and 2) life sciences customers by sharing critical disease insights not available anywhere else. Everyone at AllStripes is driven by a deep commitment to our mission, a passion for problem solving, and an openness to vulnerability. We regard our culture as one of the products we offer. As a team, we practice conscious leadership, where we are committed to supporting each other to be curious, open, and playful in order to build a connected, creative, and energetic...